Study guide

14.1 The Eleven Current GCP Principles

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

14.1 The Eleven Current GCP Principles

Key Takeaways Explain This Topic AI

E6(R3) has eleven main principles with related subprinciples.

Quality should be built into design and conduct, with proportionate processes.

Annex 1 and Appendices A–C organise operational responsibilities and key trial records.

Last updated: October 2026

The Eleven Current GCP Principles

Note

Good Clinical Practice (GCP) is a unified international ethical and quality standard for designing, conducting, performing, monitoring, auditing, recording, analyzing, and reporting clinical trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that clinical trial data are credible.

The global architecture of clinical trial regulation rests upon the standards established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) . For the professional Clinical Research Associate (CRA), Good Clinical Practice is not merely an abstract regulatory ideal; it is the operational playbook that governs every site assessment, document review, and data verification activity conducted in the field.

The current 11-principle framework

E6(R3) groups GCP into eleven main principles. Read their subprinciples together rather than treating a numbered slogan as the answer to every scenario.

Main principle Practical implication for a CRA

1. Ethical conduct and participant protection Scientific or commercial aims do not override rights, safety and well-being

2. Meaningful voluntary consent Verify informed decisions, understandable information and appropriate documentation

3. Independent ethics review Establish approval before trial participation and continuing oversight appropriate to risk

  • 4. Scientific soundness Use current knowledge and a design capable of answering the research question
  • 5. Qualified people Match education, training and experience to each activity
  • 6. Quality built into design and conduct Identify important factors before failures occur
  • 7. Proportionate processes Focus safeguards and checks on risks and the importance of the data

8. A clear, scientifically sound, feasible protocol Give sites actionable requirements rather than ambiguous procedures

9. Reliable results Use fit-for-purpose tools and protect data throughout the lifecycle

10. Clear documented roles and responsibilities Preserve sponsor and investigator oversight of transferred/delegated work

11. Proper investigational-product management Protect product quality, protocol use and appropriate traceability

The old thirteen-principle R2 list is not the current numbering. More importantly, R3 makes quality, proportionality, fit-for-purpose systems and clear responsibilities explicit. A detailed checklist cannot compensate for a design that creates avoidable participant burden or fails to measure the primary outcome reliably.

Consider a study with frequent assessments that do not answer its objectives. Quality by design asks whether those assessments are necessary and feasible before initiation. Removing unnecessary procedures through the authorised design process can reduce burden and error. A site cannot simply omit them after initiation: proportionate quality management must operate through the protocol and controlled change process.

Consider an electronic data transfer that faithfully copies an incorrect field mapping. A successful transfer count does not establish reliable results. The team needs suitable mapping, validation/reconciliation, relevant metadata and review of critical outputs. The CRA contributes by recognising clinical inconsistencies, verifying the site process and escalating a system defect to the responsible function.

Consider a sponsor that transfers monitoring to a service provider. A contract clarifies activities but does not eliminate sponsor oversight. Similarly, an investigator can delegate a qualified coordinator's work but remains responsible for site oversight. Establish who acts, who reviews, what evidence is retained and where concerns are escalated.

Navigating the current guideline

The final E6(R3) Principles and Annex 1 were adopted at ICH Step 4 on January 6, 2025. ACRP's current CCRA reference links to that document. Use Annex 1 for IRB/IEC, investigator, sponsor and data governance responsibilities. Appendix A concerns the IB, Appendix B the protocol, and Appendix C essential records. An old reference such as R2 section 4.8 should not be relabelled as the same number in R3.

The principles apply across suitable trial approaches; Annex 1 is not a prohibition on remote interactions or electronic information. Assess which activities and technologies are appropriate to the trial and how participant protection, oversight, access and data reliability are maintained. Do not assume that an additional or future annex is part of the certification reference merely because it has been announced or published. Confirm ACRP's linked reference list for the test period.

E6(R3) distinguishes guidance from applicable regulatory requirements. In real trial conduct both matter. On the CCRA exam, ACRP specifies its international ICH reference framework rather than FDA form numbers or country-specific portals. When a task example mentions a local concept, practise the underlying decision: verify an investigator's standing, protect privacy, document a safety report or confirm authorisation.

A proportionate approach requires justification, not reduced care. A high-risk first-in-human dose process may need intensive oversight. A lower-risk process may use fewer manual checks when validated controls and central surveillance provide adequate assurance. Document the rationale, examine experience and adjust controls when new information changes risk.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ACRP CCRA Exam Content Outline .